Literature DB >> 20151967

External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database.

Anna E Teeter1, Leon Sun, Judd W Moul, Stephen J Freedland.   

Abstract

OBJECTIVE: To validate a model previously developed using the Shared Equal Access Regional Cancer Hospital (SEARCH) database to predict the risk of aggressive recurrence after surgery, defined as a prostate-specific antigen (PSA) doubling time (DT) of <9 months, incorporating pathological stage, preoperative PSA level and pathological Gleason sum, that had an area under the curve (AUC) of 0.79 using a cohort of men from the Duke Prostate Center (DPC). PATIENTS AND METHODS: Data were included from 1989 men from the DPC database who underwent RP for node-negative prostate cancer between 1987 and 2003. Of these men, 100 had disease recurrence, with a PSADT of <9 months, while 1889 either did not have a recurrence but had > or =36 months of follow-up or had a recurrence with a PSADT of > or =9 months. We examined the ability of the SEARCH model to predict aggressive recurrence within the DPC cohort, and examined the correlation between the predicted risk of aggressive recurrence and the actual outcome within DPC.
RESULTS: The SEARCH model predicted aggressive recurrence within DPC with an AUC of 0.82. There was a strong and significant correlation between the predicted risk of aggressive recurrence based on the SEARCH tables and the actual outcomes within DPC (r= 0.68, P < 0.001), although the model predictions tended to be slightly higher than the actual risk.
CONCLUSIONS: The SEARCH model to predict aggressive recurrence after RP predicted aggressive recurrence in an external dataset with a high degree of accuracy. These tables, now validated, can be used to help select men for adjuvant therapy and clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151967      PMCID: PMC2891130          DOI: 10.1111/j.1464-410X.2010.09214.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  13 in total

1.  Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

Authors:  Richard K Valicenti; Michelle DeSilvio; Gerald E Hanks; Arthur Porter; Harmar Brereton; Seth A Rosenthal; William U Shipley; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-18       Impact factor: 7.038

2.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

3.  Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Authors:  Stephen J Freedland; Christopher L Amling; Frederick Dorey; Christopher J Kane; Joseph C Presti; Martha K Terris; William J Aronson
Journal:  Urology       Date:  2002-10       Impact factor: 2.649

4.  Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer.

Authors:  M W Kattan; T M Wheeler; P T Scardino
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

5.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.

Authors:  Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

6.  Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

7.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

8.  Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation.

Authors:  Peter C Albertsen; James A Hanley; David F Penson; Judith Fine
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

9.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Authors:  Anthony V D'Amico; Judd W Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen
Journal:  J Natl Cancer Inst       Date:  2003-09-17       Impact factor: 13.506

10.  Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?

Authors:  Florian R Schroeck; William J Aronson; Joseph C Presti; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  BJU Int       Date:  2008-11-18       Impact factor: 5.588

View more
  1 in total

1.  Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group.

Authors:  Anna E Teeter; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2013-07       Impact factor: 2.649

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.